abstract |
Provided herein are combinations comprising HDACi and a PD-1 inhibitor that are suitable for use in treating cancer, including reducing and/or preventing cancer metastasis. This combination is also suitable for the treatment of cancer that has previously been treated with a PD-L1 inhibitor. |